Phentermine/Topiramate ER Weight‑Loss Therapy: Evidence‑Based Recommendations
Dosing and Titration
Expected Efficacy
Pre‑Treatment Safety Screening
Absolute Contraindications
Baseline Clinical Assessments
Monitoring During Therapy
Visit Schedule
Parameters to Assess at Each Visit
Patient Selection
Eligibility Criteria
Additional Therapeutic Benefits
Critical Safety Considerations
Teratogenic Risk
Contraindication Related to Hypertension
Initiating Phentermine/Topiramate for Weight Loss
Initial Dosing and Titration
- The American Gastroenterological Association recommends starting with phentermine/topiramate ER 3.75/23 mg daily for 14 days, then increasing to 7.5/46 mg daily as the maintenance dose, with further escalation to a maximum of 15/92 mg daily if needed based on weight loss response 2, 3
- The initial dosing protocol involves starting with 3.75/23 mg (phentermine/topiramate) once daily for 14 days, followed by an increase to 7.5/46 mg once daily as the standard maintenance dose 2, 3
- Further titration if needed can escalate through 11.25/69 mg, then to a maximum 15/92 mg daily 4, 3
Efficacy Assessment and Dose Adjustment
- Evaluate weight loss at 12 weeks to determine whether to continue, increase dose, or discontinue, with expected weight loss of 7.8% at 7.5/46 mg dose and 9.8% at 15/92 mg dose compared to 1.2% with placebo 2, 3
- If less than 3% weight loss at 12 weeks, consider increasing the dose 3
- If less than 5% weight loss at 12 weeks on maximum dose (15/92 mg), discontinue the medication 2, 3
Patient Selection and Contraindications
- Ideal candidates include younger patients requiring appetite suppression, and those with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities 4, 2
- Contraindications and poor candidates include uncontrolled hypertension, active coronary disease, history of nephrolithiasis, hyperthyroidism, glaucoma, anxiety, or insomnia, and history of drug abuse or recent MAOI use 4
- Women of childbearing potential without reliable contraception should not use phentermine/topiramate due to the risk of orofacial clefts if exposed during the first trimester 2, 3
Critical Safety Considerations
- Before initiating treatment, obtain a pregnancy test in women of childbearing potential, counsel about teratogenicity risk and reduced efficacy of hormonal contraceptives, and assess for contraindications 2, 3, 4
- Common side effects to anticipate include paresthesias, dizziness, dysgeusia, insomnia, constipation, and dry mouth 2, 3
Monitoring Requirements
- Regular follow-up schedule includes monthly visits for the first 3 months, and every 3 months thereafter, with monitoring of blood pressure and heart rate at each visit, and repeat pregnancy tests as clinically indicated 2, 5